Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jul 28, 2016
Last Price Change Open Day High 52-Week High
0.50  down   (4.401%) 11.38 11.38 82.75
Volume Previous Close Day Low 52-Week Low
267,524 11.36 10.69 9.58

View all »   RSSRecent Releases

Jun 28, 2016
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid

May 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results